Comprehensive Genetic Testing for Pediatric Hypertrophic Cardiomyopathy Reveals Clinical Management Opportunities and Syndromic Conditions

Dana B. Gal1,2 · Ana Morales3 · Susan Rojahn3 · Tom Callis3 · John Garcia3 · James R. Priest1,4 · Rebecca Truty3 · Matteo Vatta3 · Robert L. Nussbaum3 · Edward D. Esplin3 · Seth A. Hollander1,2

Received: 1 July 2021 / Accepted: 25 October 2021 / Published online: 29 October 2021
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021

Abstract
Hypertrophic cardiomyopathy (HCM) has historically been diagnosed phenotypically. Through genetic testing, identification of a molecular diagnosis (MolDx) is increasingly common but the impact on pediatric patients is unknown. This was a retrospective study of next-generation sequencing data for 602 pediatric patients with a clinician-reported history of HCM. Diagnostic yield was stratified by gene and self-reported race/ethnicity. A MolDx of HCM was identified in 242 (40%) individuals. Sarcomeric genes were the highest yielding, but pathogenic and/or likely pathogenic (P/LP) variants in syndromic genes were found in 36% of individuals with a MolDx, often in patients without documented clinical suspicion for a genetic syndrome. Among all MolDx, 73% were in genes with established clinical management recommendations and 2.9% were in genes that conferred eligibility for clinical trial enrollment. Black patients were the least likely to receive a MolDx. In the current era, genetic testing can impact management of HCM, beyond diagnostics or prognostics, through disease-specific guidelines or clinical trial eligibility. Genetic testing frequently can help identify syndromes in patients for whom syndromes may not be suspected. These findings highlight the importance of pursuing broad genetic testing, independent of suspicion based on phenotype. Lower rates of MolDx in Black patients may contribute to health inequities. Further research is needed evaluating the genetics of HCM in underrepresented/underserved populations. Additionally, research related to the impact of genetic testing on clinical management of other diseases is warranted.

Keywords Hypertrophic cardiomyopathy · Pediatrics · Genetic testing · Disparities

Abbreviations
HCM Hypertrophic cardiomyopathy
MolDx Molecular diagnosis
P/LP Pathogenic/likely pathogenic

Introduction
In pediatric cardiology, genetic testing is now a well-accepted part of clinical practice, and for certain diseases results in both improved diagnostics and clinical management guidance when effectively implemented [1]. For patients with hypertrophic cardiomyopathy (HCM), 40–70% of affected adults have a causal pathogenic variant identified [2, 3]. However, the impact of a molecular diagnosis (MolDx) on the clinical management of this serious disease in pediatric patients is not well understood [4].

HCM is a serious and potentially fatal cardiomyopathy [5]. Although HCM remains a phenotypic diagnosis, it has
become increasingly possible with improved genetic testing to couple a HCM phenotype with a MolDx identifying a disease-causing variant responsible for either an isolated cardiomyopathy or a pleomorphic genetic syndrome that includes a cardiac defect [5]. Despite these advances, only a limited number of small studies have examined the clinical utility of genetic testing of children with HCM, and it is not known how many patients actually receive any clinical benefit from a MolDx, either in the form of genotype-specific management and therapies or newfound eligibility for enrollment in clinical trials [4, 6]. Additionally, genetic information related to HCM in non-White populations is lacking [7]. Disparities in access to a MolDx based on race or ethnicity may result in inequity in targeted therapeutics. We hypothesized that in the modern era, a MolDx can guide clinical management through disease-specific guidelines and/or clinical trial eligibility in pediatric HCM. We also sought to assess the impact of race/ethnicity on the ability to provide a MolDx.

**Methods**

Personal and family history information from testing requisition forms were reviewed for 602 patients under 18 years of age who were referred to Invitae for germline genetic testing for a clinician-reported history of HCM between 2013 and 2020. The cohort included eligible patients referred for genetic testing from multiple medical centers and community clinics nationwide. All patient data were de-identified before analysis under Western Independent Review Board protocol number 1167406.

Up to 150 genes were analyzed for each patient. Ordering clinicians typically selected standard gene panels for cardiomyopathies (e.g., Invitae Hypertrophic Cardiomyopathy Panel, Invitae Cardiomyopathy Comprehensive Panel, Invitae Arrhythmia and Cardiomyopathy Panel) all of which are customizable by the clinician (Supplementary Table 1). Adding more genes to a test did not increase cost. Sample types included blood and saliva. DNA was processed and subjected to paired-end sequencing on an Illumina next-generation sequencing platform [8]. Pathogenic/likely pathogenic (P/LP) variants, including single-nucleotide variants, small indels, and large deletions/duplications, such as copy number variants, along with other complex rearrangements were confirmed using orthogonal technology per Invitae standard operating practices [8]. MolDx was defined as either a P/LP variant in an autosomal dominant gene or two P/LP variants in an autosomal recessive (e.g., homozygotes).

Variants were subjected to clinical interpretation using Invitae’s proprietary methodology, Sherloc, a refinement of the 2015 guidelines from the American College of Medical Genetics and Genomics and the Association for Molecular Pathology [9]. Only P/LP variants were included in the analysis of yield; gene-specific yields were calculated based on the number of patients tested on each gene. Diagnostic yield was stratified by gene, age at testing, and patient-reported race/ethnicity and MolDx results were reviewed for syndromic genes with pediatric presentation and further stratified by Rasopathy and non-Rasopathy syndromes as listed in Supplementary Table 2. To determine how a MolDx can impact clinical management beyond diagnostic or prognostic knowledge, we assessed clinical trial enrollment eligibility by searching clinicaltrials.gov using the following parameters: interventional, age < 18 years, gene name/genetic diagnosis used as part of recruitment, and status = recruiting (search conducted 5/13/2020). We also compared MolDx results with the availability of guideline-based recommendations to determine the impact of MolDx on precision therapeutic intervention. Finally, for probands with MolDx in syndromic genes, we reviewed all available clinical documentation submitted by ordering clinicians to assess whether the probands had syndromic presentations. Of note, submission of clinical information is optional, so not all patients had complete and available clinical information.

**Results**

**Molecular Diagnosis of Isolated HCM**

A total of 602 probands with a clinician-reported history of HCM were included (Table 1). Of these probands, 52% (313/602) had up to 60 genes sequenced on panels that included HCM genes and 42% (255/602) had up to 150 genes sequenced on the Invitae Arrhythmia and Cardiomyopathy Comprehensive Panel or a combination of other panels. The other 6% (36/602) underwent testing with more narrowly defined Noonan syndrome or RASopathy panels. P/LP variants were identified in 42% (255/602) of probands. A compendium of all P/LP variants observed is available in Supplementary Table 2. Of all probands with ≥ 1 P/LP variant, 94% (242/255) had findings consistent with a MolDx of HCM, accounting for an overall 40% (242/602) diagnostic yield for HCM. The other 13 probands harbored P/LP variants that did not result in a MolDx for HCM. Of these, 7 were carriers for variants in autosomal recessive genes associated with HCM and 6 had variants related to disorders that have not been associated with HCM in pediatric patients (5 had a MolDx and 1 was a carrier) (Fig. 1).

When stratified by self-reported race/ethnicity, the number of probands with P/LP variants identified exhibited a wide range: 65% (20/31) among Asian, 43% (103/239) among White, and 24% (21/89) among Black individuals. Among probands who self-identified as Hispanic, 46% (55/119) had a P/LP variant. The P/LP yield in Black...
patients with HCM was 24%, significantly less than the 46% yield observed in the remainder of the cohort \( (p = 0.0002) \).

Consistent with prior reports, the highest yielding genes for a MolDx were the sarcomeric genes \( MYBPC3 \) (13%; 75/565 tested) and \( MYH7 \) (12%; 66/565 tested). Among the 242 probands with a MolDx of HCM, 177 (73%) had a P/LP variant in a gene with established clinical management recommendations and 7 (2.9%) would be potentially eligible for clinical trial enrollment based on their germline test result (Table 2, Supplementary Table 3). Clinical management would not be impacted directly for the 7 probands found to be carriers of P/LP variants in recessive HCM genes, but these results could affect future reproductive considerations such as carrier screening for a P/LP variant in the same gene in partners or family members and their partners.

Multiple variants each independently consistent with a MolDx of HCM were reported in 5 probands (1%; 5/602), including one proband with multiple variants in \( MYBPC3 \). Two additional probands harbored a P/LP consistent with a MolDx of HCM as well as a P/LP in \( TTR \), which is consistent with a MolDx of syndromic adult-onset HCM. One proband harbored a P/LP variant in \( MYBPC3 \) and a P/LP variant in \( KCNQ1 \) (a non-HCM gene), each consistent with a separate MolDx. Additionally, homozygous variants in \( GAA \) were identified in 1 proband and in \( MYBPC3 \) in 2 probands.

**Molecular Diagnosis of Syndromic Disease**

Among the 242 probands with a MolDx of HCM, 86 (36%) were found to harbor a variant in a gene associated with a syndromic presentation. Most of the syndromic findings were in Rasopathy-associated genes (70%, 60/86) and 30% (26/86) were in genes associated with non-Rasopathy syndromes. Review of clinical information provided by ordering clinicians showed that 44% (38/86) of the probands with a syndromic MolDx of HCM had no reported clinical suspicion of syndromic disease at the time of testing. Figure 1

---

**Table 1** Patient characteristics, \( N=602 \)

| Characteristic            | \( n \) (%) |
|---------------------------|-------------|
| **Ages, years**           |             |
| 0–2                       | 117 (19.4)  |
| 3–5                       | 37 (6.1)    |
| 6–8                       | 35 (5.8)    |
| 9–11                      | 66 (11.0)   |
| 12–14                     | 163 (27.1)  |
| 15–17                     | 184 (30.6)  |
| **Gender**                |             |
| Male                      | 413 (68.6)  |
| Female                    | 189 (31.4)  |
| **Ancestry**              |             |
| Ashkenazi Jewish          | 1 (0.2)     |
| Asian                     | 31 (5.1)    |
| Black                     | 89 (14.8)   |
| Hispanic                  | 119 (19.8)  |
| Mediterranean             | 2 (0.3)     |
| Multiple*                 | 35 (5.8)    |
| Native American           | 3 (0.5)     |
| Unknown                   | 83 (13.8)   |
| White                     | 239 (39.7)  |

*Multiple includes combinations of 2 or more of the following self-reported ancestries: Ashkenazi Jewish, Asian, Black, Hispanic, Mediterranean, Native American, Pacific Islander, and White

---

![Fig. 1 Flowchart of the entire cohort. Of the entire cohort, 40% had a molecular diagnosis of HCM. Of these, 76% had disease-specific clinical management guidelines or conferred clinical trial eligibility. In green are the groups for whom genetic testing could impact clinical management of HCM; yellow indicates the groups which may have care of non-HCM disease or future considerations impacted by genetic testing; red demonstrates the patients for whom no pathogenic or likely pathogenic variant was identified. Parenthetical numbers indicate the number of patients in each group. P/LP pathogenic/likely pathogenic. HCM hypertrophic cardiomyopathy](image-url)
| Gene       | Management recommendations/trial eligibilitya,b                      | Source                  |
|------------|---------------------------------------------------------------------|-------------------------|
| ACADVL     | - Extracardiac disease monitoring/management, pregnancy considerations | PMID: 20301763          |
|            | - Pharmacologic and dietary considerations                           |                         |
|            | Clinical trial eligibility: NCT03773770                              |                         |
| ACTC1      | - Non-HCM cardiac disease monitoring/management                      | PMID: 28912181          |
| AGT        | - Pharmacologic and dietary considerations                           | PMID: 20631546          |
| BRAF       | - Extracardiac disease monitoring/management                         | PMID: 23312968          |
| CACNA1C    | - Non-HCM cardiac and extracardiac disease monitoring/management      | PMID: 25180280          |
| CAPN3      | - Extracardiac disease monitoring/management                         | PMID: 25313375          |
| CBS        | - Non-HCM cardiac and extracardiac disease monitoring/management      | PMID: 27778219          |
|            | - Dietary considerations                                             |                         |
| CPT2       | - Dietary and pharmacologic considerations                           | PMID: 20301431          |
| DES        | - Non-HCM cardiac disease monitoring/management                      | PMID: 28190577          |
|            | - Non-HCM cardiac and extracardiac disease monitoring/management      | PMID: 31078652          |
| FHL1       | - Extracardiac disease monitoring/management                         | PMID: 29633897          |
|            | - Extracardiac disease monitoring/management                         | PMID: 20301609          |
|            | - Pharmacologic considerations                                       |                         |
| FKN        | - Extracardiac disease monitoring/management                         | PMID: 25825463          |
|            | - Pharmacologic considerations                                       |                         |
| FLNC       | - Non-HCM cardiac disease monitoring/management                      | PMID: 31078652          |
| GAA        | - Non-HCM cardiac and extracardiac disease monitoring/management      | PMID: 16702877          |
|            | Clinical trial eligibility: NCT02354651, NCT01410890, NCT03911505, NCT04049760 |                         |
| HRAS       | - Non-HCM cardiac and extracardiac disease monitoring/management      | PMID: 31222966          |
| KRAS       | - Non-HCM cardiac and extracardiac disease monitoring/management      | PMID: 25180280          |
| KCNQ1      | - Non-HCM cardiac disease monitoring/management                      | PMID: 20301308          |
| LAMP2      | - Non-HCM cardiac disease monitoring/management                      | PMID: 25228319          |
|            | Clinical trial eligibility: NCT03882437                              |                         |
|            | - Extracardiac disease monitoring/management                         | PMID: 25228319          |
| MYBPC3     | - Non-HCM cardiac disease monitoring/management                      | PMID: 28912181          |
| MYH7       | - Non-HCM cardiac disease monitoring/management                      | PMID: 28912181          |
| MYL2       | - Non-HCM cardiac disease monitoring/management                      | PMID: 28912181          |
| MYL3       | - Non-HCM cardiac disease monitoring/management                      | PMID: 28912181          |
| NF1        | - Non-HCM cardiac and extracardiac disease monitoring/management      | PMID: 31010905          |
| PKP2       | - Non-HCM cardiac disease monitoring/management                      | PMID: 3107852           |
| PRKAG2     | - Non-HCM cardiac and extracardiac disease monitoring/management      | PMID: 26729852          |
| PTPN11     | - Extracardiac disease monitoring/management                         | PMID: 23312968          |
| RAF1       | - Extracardiac disease monitoring/management                         | PMID: 23312968          |
| RIT1       | - Extracardiac disease monitoring/management                         | PMID: 23312968          |
| RYR1       | - Extracardiac disease monitoring/management                         | PMID: 29600483;         |
|            | - Pharmacologic, surgical, and environmental considerations          | PMID: 26238698          |
| SOS1       | - Extracardiac disease monitoring/management                         | PMID: 23312968          |
| TNNC1      | - Non-HCM cardiac disease monitoring/management                      | PMID: 28912181          |
| TNNI3      | - Non-HCM cardiac disease monitoring/management                      | PMID: 28912181          |
| TNNI2      | - Non-HCM cardiac disease monitoring/management                      | PMID: 28912181          |
| TPM1       | - Non-HCM cardiac disease monitoring/management                      | PMID: 28912181          |
| TTR        | - Extracardiac disease monitoring/management                         | PMID: 20301373          |

\(^a\)Based on gene or clinical diagnosis-specific guidelines. Broad recommendations, such as those included in cardiogenetics guidelines addressing the genetic evaluation of HCM or cardiomyopathies, are not included.

\(^b\)Search conducted on 5/13/2020 in clinicaltrials.gov using the following parameters: intervention, < 18 years of age, gene name or genetic diagnosis used as part of recruitment, and status = recruiting.
provides a summary of the overall breakdown of the above-described groups.

**Age at Testing and Gene Type**

A MolDx of syndromic HCM was associated with a much earlier age at testing with a median age at testing of syndromic HCM of 4 years vs. median age at testing of isolated HCM of 12 years ($p < 0.001$) (Fig. 2). Individuals with a Rasopathy MolDx contributed significantly to the earlier age at testing (median age at testing of Rasopathy MolDx of 1 year vs. median age at testing of non-Rasopathy MolDx of 13.5 years, $p < 0.001$).

**Family Variant Testing**

Cascade testing of 434 family members was carried out in the families of 129 unrelated probands. On average, 3.4 family members were tested per proband (range 1–46). Of the 434 family members tested, 178 (41.0%) were identified as carrying ≥ 1 HCM disease-causing variant. Family variant testing was accomplished in at least one at-risk relative for 121/242 (50%) probands with a MolDx of HCM.

**Discussion**

This study is novel in determining how often a MolDx goes beyond providing just a diagnosis to impacting clinical management in HCM among pediatric patients. A MolDx was determined in 40 percent of patients, which is comparable to previously published rates [2, 5]. However, we observed significant disparities in MolDx yield by race/ethnicity, with a significantly reduced ability to provide a MolDx for Black probands. Additionally, we show that among all probands who received a MolDx, three-quarters had P/LP variants in genes with established management recommendations and/or gene-specific clinical trial eligibility. Precision medicine remains a developing field and some of the available guidelines inform the management of categories of variants, as opposed to being gene specific. For example, the diagnostic variants in the sarcomeric genes MYH7 and TNNT2 have the same management recommendations. As precision medicine progresses, it is possible recommendations will become increasingly variant specific. As this body of knowledge is nascent, guidelines continue to be developed and ultimately will need large-scale validation.

This study is also novel in showing that 38 of the 86 (44%) patients in this cohort with a MolDx of a syndromic form of HCM were not reported by ordering clinicians to

---

**Fig. 2** Plot demonstrating count of syndromic versus non-syndromic cases of HCM stratified by age at testing. Syndromic HCM was associated with an earlier age when compared with non-syndromic HCM, although both types of cases were diagnosed across the entire age range.
have clinical evidence of a genetic syndrome at the time of genetic testing. The 2011 ACCF/AHA guideline for HCM distinguishes between isolated HCM (patients with sarcomeric variants/without extracardiac findings and unresolved genetic substrate) and patients with left ventricular hypertrophy as part of a syndrome, including extracardiac findings or metabolic disease [10]. This distinction is upheld in the updated 2020 AHA/ACC guideline which refers to patients with systemic disorders and left ventricular hypertrophy as “HCM Phenocopies” [7]. However, distinguishing between these patients based on phenotype alone is often difficult, particularly early in life when subtle facial dysmorphisms or other extracardiac manifestations may not be apparent and HCM may be the only evident manifestation of a genetic syndrome. By showing that 38 patients in whom clinical evidence of a syndrome was not reported in fact had P/LP variants in genes associated with a syndromic form of HCM, our results help define and quantify the number of patients who would have been missed or misdiagnosed without comprehensive multigene panel genetic testing. Prior reports with smaller cohorts have reported syndromic variants among patients with seemingly isolated HCM, although at lower rates than in our cohort [11]. One factor potentially leading to a large number of patients with syndromic diagnoses being missed is the strategy of ordering the narrowest panel of gene tests based on a clinician's hypothesis of likely genetic etiology from patient phenotypes [12, 13]. This approach of limiting the number of genes included on the panel likely results in missed identification of syndromic patients who would otherwise have benefitted from earlier intervention and gene-based precision clinical management had their syndrome been diagnosed genetically earlier in life [10, 13]. The inverse is likely also true that testing too narrowly for a suspected syndromic mutation based on phenotype may result in missed or delayed diagnosis of other syndromes or non-syndromic disease.

We also found that nearly half of proband relatives who underwent cascade family variant testing were found to have HCM disease-causing variants. The role of genetic testing in screening for disease susceptibility among asymptomatic family members has been central to the discussion of the clinical utility of genetic testing [7, 14]. While not impacting the clinical management of the probands, identification of affected or at-risk family members does allow for appropriate screening for clinical disease or, for those with negative testing, relief from unnecessary cardiac surveillance testing and anxiety over risk for disease. Effective cascade family variant testing also supports efficient health care resource utilization by helping to focus cardiac surveillance on family members with confirmed genetic risk. As precision medicine continues to develop, cascade testing lends support to genetic testing of probands as a form of changing clinical management.

In this cohort, it is notable that a MolDx was least frequently achieved for Black patients despite epidemiologic data showing that HCM occurs at similar rates among Black populations compared to other races and ethnicities, with some reports suggesting HCM may be more common in this group [15–17]. This lower rate of achieving a MolDx for Black patients has also been described among adult HCM cohorts [18]. There are several potential reasons for this lower yield, many of which are confounded by challenges with access to genetic testing among non-White populations. Indeed, the 2020 AHA/ACC guideline does note that the non-White HCM population has fewer described high-quality genetic data [7]. It is possible that novel variants found in Black populations have not been studied enough to allow them to be classified as anything except variants of unknown significance, as has been the case for other diseases [19]. Lack of knowledge of variants in non-White population also introduces the risk for misclassification of benign variants as pathogenic [20]. It is also possible that a greater proportion of the genes involved in HCM in Black patients are still unknown and untested. There may also be environmental, non-genetic factors that can contribute to the development of HCM which affect Black children disproportionately. Finally, the pre-test probability for a MolDx of HCM in Black patients may be lower because of the contribution of racial bias in the actual definition of HCM. Black patients were underrepresented in the development of Z-scores so it possible that non-pathologic LVH among Black patients could be misclassified as HCM, reducing the likelihood that a MolDx would be identified [20].

While investigating the reason for this disparity was beyond the scope of this study, the differential ability to provide a MolDx for Black HCM patients likely confers a reduced ability to provide targeted clinical management for these patients, potentially contributing to racial health inequities. A known impact of the relative paucity of sequencing data in underrepresented populations is the risk for misclassification of benign variants as disease causing [21]. There are known systemic and individual-level barriers to genetic testing among Black patients ranging from baseline knowledge and apprehensions about testing related to historical injustices to differences in coverage for genetic testing between public and private insurances [22, 23]. These issues must be addressed. Improved understanding and increased access to genetic testing for HCM in Black patients are needed to ultimately offer the same benefits from MolDx provided to individuals of other races or ethnicities.

While we focused specifically on HCM, it is reasonable to theorize that our findings relate to other diseases that have historically relied upon phenotypic or clinical and diagnosis. Through genetic testing, we can now confirm or refute these clinical diagnoses. Indeed, we now understand patients with the same phenotype may have different underlying
mutations warranting different management strategies [24]. Conversely, patients with different phenotypic presentations may share the same genetic substrate [11, 25]. Our findings highlight the importance of broad, unbiased genetic testing and demonstrate how genetic testing results can help patients and their families. Knowledge that a MolDx can impact clinical management, including acute treatment, may influence general practitioners, who may be less comfortable utilizing genetic testing, to pursue it more frequently [26, 27]. Unfortunately, our findings also recapitulate that diminished access to precision medicine due to inadequate genetic understanding of Black patients may exacerbate ongoing, multifactorial health inequities.

This study has several limitations, including its retrospective design and the inability to access full clinical data for patients. In particular, we were unable to definitively determine if patients with syndromic mutations had extracardiac disease. Although the reported clinical data submitted with testing orders indicated suspicion of syndromic disease in some cases, we cannot be certain of the details regarding why syndromes were or were not suspected. Similarly, we did not have sufficient clinical data to evaluate the correlation between phenotypes and MolDx. Additionally, it is possible that some negative results were a reflection of providers ordering smaller panels that did not analyze the gene(s) relevant to their patient’s condition. We also cannot report whether the clinical management recommendations based on MolDx were implemented or whether patients eligible for clinical trials were actually enrolled. Additionally, as genetic testing has proliferated in the clinical setting, concerns have been raised regarding the emotional impact on families awaiting results, confidentiality of results, and results that include secondary findings or variants of unknown significance [28]. Other fears such as impact on insurability are also common among families [28]. As with any intervention in medicine, these concerns and risks must be weighed against potential benefit and, fortunately, many may be mitigated with genetic counseling and other best practices both prior to testing and after receiving results of testing [29, 30].

**Conclusion**

Almost half of our cohort of patients with clinically diagnosed HCM received a MolDx, a substantial portion of which were syndromic. The majority of patients with a MolDx of HCM had P/LP variants in genes with established management recommendations and/or gene-specific clinical treatment trial eligibility. Some of the currently available management recommendations, particularly for non-syndromic HCM, are for categories of variants rather than being gene specific. The diagnostic yield in Black patients with HCM was significantly less than that of other populations, underscoring the need for genetic research in this historically understudied population and suggesting additional genetic etiologies of HCM have yet to be elucidated. These data reinforce the importance of comprehensive multigene panel genetic testing to facilitate an accurate and early diagnosis and demonstrate the clinical utility of genetic testing in treatment planning. This may be relevant for other diseases of genetic etiology which have traditionally been diagnosed based on clinical or phenotypic findings.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00246-021-02764-1.

**Author Contributions** Dr. DBG—Methodology, formal analysis, visualization, writing the original draft, and project administration. Ms. AM—Methodology, data curation, formal analysis, visualization, and writing, reviewing, and editing of the manuscript. Ms. SR—Methodology, data curation, formal analysis, visualization, and writing, reviewing, and editing of the manuscript. Dr. TC—Formal analysis, and writing, reviewing, and editing of the manuscript. Dr. JG—Formal analysis and writing, reviewing, and editing of the manuscript. Dr. JRP—Methodology, formal analysis, visualization, and writing, reviewing, and editing of the manuscript. Dr. RT—Formal analysis and writing, reviewing, and editing of the manuscript. Dr. MV—Formal analysis and writing, reviewing, and editing of the manuscript. Dr. RLN—Formal analysis and writing, reviewing, and editing of the manuscript. Dr. EDE—Conceptualization, methodology, resources, investigation, data curation, formal analysis, and writing, reviewing, and editing of the manuscript. Dr. SAH—Methodology, formal analysis, visualization, writing, reviewing, and editing of the manuscript, and supervision.

**Funding** This work was not supported by any funding source.

**Data Availability** Not applicable.

**Code Availability** Not applicable.

**Declarations**

**Conflict of interest** AM, TC, JG, SR, RT, MV, RLN, and EDE are employees and stockholders of Invitae. JRP is an employee and stockholder of BioMarin Pharmaceutical which has publicly disclosed early-stage therapeutic approaches to HCM. All other authors have indicated that they have no potential conflict of interest to disclose.

**Ethical Approval** This study was approved by the Western Independent Review Board, protocol number 1167406.

**Consent to Participate** Not applicable.

**Consent for Publication** All authors are responsible for reported research and have approved the manuscript as submitted.

**References**

1. Schwartz PJ, Ackerman MJ, George AL, Wilde AAM (2013) Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol 62(3):169–180
2. Kindel SJ, Miller EM, Gupta R, Cripe LH, Hinton RB, Spicer RL et al (2012) Pediatric cardiomyopathy: importance of genetic and metabolic evaluation. J Card Fail 18:396–403
3. Cox GF, Sleeper LA, Lowe AM, Tovin JA, Colan SD, Orav EJ et al (2006) Factors associated with establishing a causal diagnosis for children with cardiomyopathy. Pediatrics 118:1519–1531
4. Tester DJ, Ackerman MJ (2017) Evaluating the survivor or the relatives of those who do not survive: the role of genetic testing. Cardiol Young 27:S19–S24
5. Lipshultz SE, Law YM, Asante-Korang A, Austin ED, Dipchand AI, Everitt MD et al (2019) Cardiomyopathy in children: classification and diagnosis. Circulation 140:e9–e68
6. Ritter A, Bedoukian E, Berger JH, Copenhaver D, Gray C, Krantz I et al (2019) Clinical utility of exome sequencing in infantile heart failure. Genet Med 22:423–426
7. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P et al (2020) AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. Circulation 142:e1–e74
8. Lincoln SE, Kobayashi Y, Anderson MJ, Yang S, Desmond AJ, Mills MA et al (2015) A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients. J Mol Diagn 17(5):533–544
9. Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ko Y et al (2017) Sherlock: a comprehensive refinement of the ACMG-AMP variant classification criteria. Genet Med 19(10):1105–1117
10. Gersh BJ, Baron MA, Bown RO, Dearani JA, Fisher MA, Link MS et al (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. Circulation 124(24):e783–e831
11. Kaski JP, Syrris P, Shaw A, Alapi KZ, Cordeddu V, Esteban MTT et al (2012) Prevalence of sequence variants in the RAS-Mitogen activated protein kinase signaling pathway in pre-adolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet 5:317–326
12. Arbusini E, Giuliani L, Di Toro A (2018) When genes, more than phenotype, identify different diseases: the case of nonsyndromic HTAA/D. JACC 72(6):616–619
13. Paige S, Saha P, Priest JR (2018) Beyond gene panels: whole exome sequencing for diagnosis of congenital heart disease. Circ Genom Precis Med 11(3):e002097
14. Jensen MK, Havndrup O, Christiansen M, Andersen PS, Dinnes B, Axelson A et al (2013) Penetration of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing. Circulation 127:48–54
15. Burns J, Jean-Pierre P (2018) Disparities in the diagnosis of hypertrophic obstructive cardiomyopathy: a narrative review of current literature. Cardiol Res Pract. https://doi.org/10.1155/2018/3750879
16. Movahed MR, Strootman D, Bates S, Sattur S (2010) Prevalence of suspected hypertrophic cardiomyopathy or left ventricular hypertrophy based on race and gender in teenagers using screening echocardiography. Cardiovasc Ultrasound 8:54
17. Heradien M, Goosen A, Brink PA, Moolman-Smook JC (2007) Race and gender representation of hypertrophic cardiomyopathy or long QT syndrome cases in a South African research setting. Cardiovasc J Afr 18(5):312–315
18. Eberly LA, Day SM, Ashley EA, Jacoby DL, Jefferies JL, Colan SD et al (2020) Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy. JAMA Cardiol 5(1):83–91
19. Ndugga-Kabuye MK, Issaka RB (2019) Inequities in multi-gene hereditary cancer testing: lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European. Fam Cancer 18(4):465–569
20. Lopez L, Colan S, Stylianou M, Granger S, Trachtenberg F, Frommelt P et al (2017) Relationship of echocardiographic Z scores adjusted for body surface area to age, sex, race, and ethnicity: the pediatric heart network normal echocardiogram database. Circ Cardiovasc Imaging. 10(11):e006979
21. Manrai AK, Funk BH, Rehm HL, Olesen MS, Maron BA, Szoło- P, Margulies DM, Loscalzo J, Kohane IS (2016) Genetic misdiagnoses and the potential for health disparities. N Engl J Med 375(7):655–665
22. Suther S, Kiros GE (2009) Barriers to the use of genetic testing: a study of racial and ethnic disparities. Genet Med 11(9):655–662
23. Prince AER (2015) Prevention for those who can pay: insurance reimbursement of genetic-based preventive interventions in the liminal state between health and disease. J Law Biosci 2(2):365–395
24. Chevarin M, Duffourd Y, Barnard RA, Moutton S, Lecoquierre F, Daoud F et al (2020) Excess of de novo variants in genes involved in chromatin remodeling in patients with marfanoid habitus and intellectual disability. J Med Genet 57(7):466–474
25. Lobo I (2008) Same genetic mutation, different genetic disease phenotype. Nat Educ 1(1):64
26. Hauser D, Obeng AO, Fei K, Ramos MA, Horowitz CR (2018) Views of primary care providers on testing patients for genetic risks for common chronic diseases. Health Aff (Millwood) 37(5):793–800
27. Szego MJ, Meyn MS, Shuman C, Zlotnik Shaul R, Anderson JA, Bowdin S et al (2019) Views from the clinic: healthcare provider perspectives on whole genome sequencing in pediatrics. Eur J Med Genet 62:350–356
28. Gal DB, Deutch N, Lee SSJ, Simon RT, Char D. (2021) Parental attitudes toward clinical genomic sequencing in children with critical cardiac disease. Pediatr Crit Care Med. online ahead of print. https://doi.org/10.1097/PCC.0000000000002669.
29. Clift K, Macklin S, Halverson C, McCormick JB, Abu Dabrh AM, Clift K, Macklin S (2020) Patients’ views on variants of uncertain significance across indications. J Community Genet 11:139–145
30. Hart MR, Biesecker BB, Blout CL, Christensen KD, Amendola LM, Bergstrom KL (2019) Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and healthcare costs from a multi-site study. Genet Med 21(5):1100–1110

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.